Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'extrapyramidal side effects' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 90 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Jeczmien, P; Levkovitz, Y; Weizman, A; Carmel, Z
      Post-psychotic depression in schizophrenia

      ISRAEL MEDICAL ASSOCIATION JOURNAL
    2. Haut, F; Clos, S
      Acute akathisia and sodium valproate

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    3. Kane, JM
      Extrapyramidal side effects are unacceptable

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    4. Hemsley, KM; Crocker, AD
      Changes in muscle tone are regulated by D1 and D2 dopamine receptors in the ventral striatum and D1 receptors in the substantia nigra

      NEUROPSYCHOPHARMACOLOGY
    5. Bubser, M; Backstrom, JR; Sanders-Bush, E; Roth, BL; Deutch, AY
      Distribution of serotonin 5-HT2A receptors in afferents of the rat striatum

      SYNAPSE
    6. Hassin-Baer, S; Sirota, P; Korczyn, AD; Treves, TA; Epstein, B; Shabtai, H; Martin, T; Litvinjuk, Y; Giladi, N
      Clinical characteristics of neuroleptic-induced parkinsonism

      JOURNAL OF NEURAL TRANSMISSION
    7. Crocker, AD; Hemsley, KM
      An animal model of extrapyramidal side effects induced by antipsychotic drugs: Relationship with D2 dopamine receptor occupancy

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    8. Bozikas, V; Petrikis, P; Karavatos, A
      Urinary retention caused after fluoxetine-risperidone combination

      JOURNAL OF PSYCHOPHARMACOLOGY
    9. Mihara, K; Kondo, T; Suzuki, A; Yasui, N; Ono, S; Otani, K; Kaneko, S
      No relationship between-141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study

      PSYCHIATRY RESEARCH
    10. Wolanczyk, T; Grabowska-Grzyb, A
      Transient dystonias in three patients treated with tiagabine

      EPILEPSIA
    11. Peacock, L; Gerlach, J
      Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: Evidence of uncharted dopamine D1 receptor actions

      BIOLOGICAL PSYCHIATRY
    12. Fagan-Pryor, EC; May, DL
      Establishment of interrater reliability for a nursing Extrapyramidal Side Effects (EPS) assessment scale

      JOURNAL OF NURSING CARE QUALITY
    13. Prinssen, EPM; Koek, W; Colpaert, FC; Kleven, MS
      Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced

      BEHAVIOURAL PHARMACOLOGY
    14. Liu, SK; Chen, WJ; Chang, CJ; Lin, HN
      Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol

      NEUROPSYCHOPHARMACOLOGY
    15. Bruggeman, R; Heeringa, M; Westerink, BHC; Timmerman, W
      Combined 5-HT2/D-2 receptor blockade inhibits the firing rate of SNR neurons in the rat brain

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    16. Hofmann, M; Seifritz, E; Botschev, C; Krauchi, K; Muller-Spahn, F
      Serum iron and ferritin in acute neuroleptic akathisia

      PSYCHIATRY RESEARCH
    17. Hilger, E; Kasper, S
      Properties and therapeutic use of atypical antipsychotics: a review

      WIENER KLINISCHE WOCHENSCHRIFT
    18. Scordo, MG; Spina, E; Romeo, P; Dahl, ML; Bertilsson, L; Johansson, I; Sjoqvist, F
      CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    19. Montgomery, AMJ; Grottick, AJ; Herberg, LJ
      Rapid recovery of self-stimulation responding from depression by clozapineis prevented by the alpha(2)-adrenoceptor agonist, clonidine

      BEHAVIOURAL PHARMACOLOGY
    20. Peacock, L; Jensen, G; Nicholson, K; Gerlach, J
      Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    21. Dorfman-Etrog, P; Hermesh, H; Prilipko, L; Weizman, A; Munitz, H
      The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: An open label study

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    22. Basile, VS; Masellis, M; Badri, F; Paterson, AD; Meltzer, HY; Lieberman, JA; Potkin, SG; Macciardi, F; Kennedy, JL
      Association of the MscI polymorphism of the dopamine D3 receptor gene withtardive dyskinesia in schizophrenia

      NEUROPSYCHOPHARMACOLOGY
    23. PEACOCK L; HANSEN L; MORKEBERG F; GERLACH J
      CHRONIC DOPAMINE D1, DOPAMINE D2 AND COMBINED DOPAMINE D1 AND D2 ANTAGONIST TREATMENT IN CEBUS-APELLA MONKEYS - ANTIAMPHETAMINE EFFECTS ANDEXTRAPYRAMIDAL SIDE-EFFECTS

      Neuropsychopharmacology
    24. Yu, JA; Kallstrom, L; Wiesel, FA; Johnson, AE
      Neurochemical changes in the entopeduncular nucleus and increased oral behavior in rats treated subchronically with clozapine or haloperidol

      SYNAPSE
    25. van Harten, PN; Kahn, RS
      Tardive dystonia

      SCHIZOPHRENIA BULLETIN
    26. Todd, CL; Grace, AA
      Interaction of benztropine and haloperidol actions on rat substantia nigradopamine cell electrophysiological activity in vivo

      BRAIN RESEARCH BULLETIN
    27. Conforti, D; Borgherini, G; Bernardis, LAF; Magni, G
      Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    28. Pallanti, S; Quercioli, L; Pazzagli, A
      Effects of clozapine on awareness of illness and cognition in schizophrenia

      PSYCHIATRY RESEARCH
    29. Vandel, P; Haffen, E; Vandel, S; Bonin, B; Nezelof, S; Sechter, D; Broly, F; Bizouard, P; Dalery, J
      Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    30. Peacock, L; Gerlach, J
      New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects

      PSYCHOPHARMACOLOGY
    31. Timmerman, W; Heijmen, M; Westerink, BHC; Bruggeman, R; den Boer, JA
      Effects of acute and chronic administration of olanzapine in comparison toclozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain

      PSYCHOPHARMACOLOGY

    32. NOVEL PIPERAZINE AND PIPERIDINE COMPOUNDS FOR SCHIZOPHRENIA

      Expert opinion on therapeutic patents
    33. CHRISTOFFERSEN CL; MELTZER LT
      REVERSAL OF HALOPERIDOL-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN CEBUS MONKEYS BY 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AND ITS ENANTIOMERS

      Neuropsychopharmacology
    34. ARNT J; SKARSFELDT T
      DO NOVEL ANTIPSYCHOTICS HAVE SIMILAR PHARMACOLOGICAL CHARACTERISTICS - A REVIEW OF THE EVIDENCE

      Neuropsychopharmacology
    35. KUMRA S; JACOBSEN LK; LENANE M; SMITH A; LEE P; MALANGA CJ; KARP BI; HAMBURGER S; RAPOPORT JL
      CASE SERIES - SPECTRUM OF NEUROLEPTIC-INDUCED MOVEMENT-DISORDERS AND EXTRAPYRAMIDAL SIDE-EFFECTS IN CHILDHOOD-ONSET SCHIZOPHRENIA

      Journal of the American Academy of Child and Adolescent Psychiatry
    36. LAMBERT MT; TRUTIA C; PETTY F
      EXTRAPYRAMIDAL ADVERSE-EFFECTS ASSOCIATED WITH SERTRALINE

      Progress in neuro-psychopharmacology & biological psychiatry
    37. LANE RM
      SSRI-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS AND AKATHISIA - IMPLICATIONSFOR TREATMENT

      JOURNAL OF PSYCHOPHARMACOLOGY
    38. BARNES TRE; MCPHILLIPS MA
      NOVEL ANTIPSYCHOTICS, EXTRAPYRAMIDAL SIDE-EFFECTS AND TARDIVE-DYSKINESIA

      International clinical psychopharmacology
    39. HALE AS
      A REVIEW OF THE SAFETY AND TOLERABILITY OF SERTINDOLE

      International clinical psychopharmacology
    40. Pearsall, R; Glick, ID; Pickard, D; Suppes, T; Tauscher, J; Jobson, KO
      A new algorithm for treating schizophrenia

      PSYCHOPHARMACOLOGY BULLETIN
    41. Allan, ER; Sison, CE; Alpert, M; Connolly, B; Crichton, J
      The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine

      PSYCHOPHARMACOLOGY BULLETIN
    42. SCHRODER J; SILVESTRI S; BUBECK B; KARR M; DEMISCH S; SCHERRER S; GEIDER FJ; SAUER H
      D-2 DOPAMINE-RECEPTOR UP-REGULATION, TREATMENT RESPONSE, NEUROLOGICALSOFT SIGNS, AND EXTRAPYRAMIDAL SIDE-EFFECTS IN SCHIZOPHRENIA - A FOLLOW-UP-STUDY WITH I-123 IODOBENZAMIDE SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY IN THE DRUG-NAIVE STATE AND AFTER NEUROLEPTIC TREATMENT

      Biological psychiatry
    43. STEEN VM; LOVLIE R; MACEWAN T; MCCREADIE RG
      DOPAMINE D3-RECEPTOR GENE VARIANT AND SUSCEPTIBILITY TO TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-PATIENTS

      Molecular psychiatry
    44. VANDEL P; BONIN B; LEVEQUE E; SECHTER D; BIZOUARD P
      TRICYCLIC ANTIDEPRESSANT-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS

      European neuropsychopharmacology
    45. GORMLEY N; WATTERS L; LAWLOR BA
      EXTRAPYRAMIDAL SIDE-EFFECTS IN ELDERLY PATIENTS EXPOSED TO SELECTIVE SEROTONIN REUPTAKE INHIBITORS

      Human psychopharmacology
    46. GERLACH J
      EXTRAPYRAMIDAL SIDE-EFFECTS

      Nordic journal of psychiatry
    47. MESZAROS K; LENZINGER E; HORNIK K; SCHONBECK G; HATZINGER R; LANGER G; SIEGHART W; ASCHAUER HN
      BIPERIDEN AND HALOPERIDOL PLASMA-LEVELS AND EXTRAPYRAMIDAL SIDE-EFFECTS IN SCHIZOPHRENIC-PATIENTS

      Neuropsychobiology
    48. NAVARRO JF; MANZANEQUE JM; VERA F; MARTINLOPEZ M; SANTIN LJ
      AMISULPRIDE, A PRESYNAPTIC D-2 D-3 DOPAMINE-RECEPTOR ANTAGONIST, INDUCES CATALEPSY IN MICE/

      Medical science research
    49. BUSATTO GF; KERWIN RW
      PERSPECTIVES ON THE ROLE OF SEROTONERGIC MECHANISMS IN THE PHARMACOLOGY OF SCHIZOPHRENIA

      JOURNAL OF PSYCHOPHARMACOLOGY
    50. KOPALA LC
      CLINICAL-EXPERIENCE IN DEVELOPING TREATMENT REGIMENS WITH THE NOVEL ANTIPSYCHOTIC RISPERIDONE

      International clinical psychopharmacology
    51. ANDREASEN NC
      IMPROVEMENT OF NEGATIVE SYMPTOMS - CONCEPTS, DEFINITION AND ASSESSMENT

      International clinical psychopharmacology
    52. FARDE L; MACK RJ; NYBERG S; HALLDIN C
      D-2 OCCUPANCY, EXTRAPYRAMIDAL SIDE-EFFECTS AND ANTIPSYCHOTIC DRUG-TREATMENT - A PILOT-STUDY WITH SERTINDOLE IN HEALTHY-SUBJECTS

      International clinical psychopharmacology
    53. LANE HY; HU OYP; JANN MW; DENG HC; LIN HN; CHANG WH
      DEXTROMETHORPHAN PHENOTYPING AND HALOPERIDOL DISPOSITION IN SCHIZOPHRENIC-PATIENTS

      Psychiatry research
    54. ARONSON SM
      COST-EFFECTIVENESS AND QUALITY-OF-LIFE IN PSYCHOSIS - THE PHARMACOECONOMICS OF RISPERIDONE

      Clinical therapeutics
    55. FUKUOKA T; NAKANO M; KOHDA A; OKUNO Y; MATSUO M
      THE COMMON MARMOSET (CALLITHRIX-JACCHUS) AS A MODEL FOR NEUROLEPTIC-INDUCED ACUTE DYSTONIA

      Pharmacology, biochemistry and behavior
    56. FELDMAN DJ; FRANK RA; KEHNE JH; FLANNERY R; BROWN D; SONI S; BYRD G; SHAH S
      MIXED D-2 5-HT2 ANTAGONISM DIFFERENTIALLY AFFECTS APOMORPHINE-INDUCEDAND AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR/

      Pharmacology, biochemistry and behavior
    57. KIKUCHI T; UWAHODO Y; TOTTORI K; NAKAI M; MORITA S
      THE ATTENUATING EFFECT OF CARTEOLOL HYDROCHLORIDE, A BETA-ADRENOCEPTOR ANTAGONIST, ON NEUROLEPTIC-INDUCED CATALEPSY IN RATS

      Psychopharmacology
    58. DEAN B; CROOK JM; OPESKIN K; HILL C; KEKS N; COPOLOV DL
      THE DENSITY OF MUSCARINIC M(1) RECEPTORS IS DECREASED IN THE CAUDATE-PUTAMEN OF SUBJECTS WITH SCHIZOPHRENIA

      Molecular psychiatry
    59. EBERHARD G
      THE EXTRAPYRAMIDAL SYMPTOMS RATING-SCALE (ESRS) AND ITS USE IN THE EVALUATION OF RISPERIDONE

      Journal of drug development and clinical practice
    60. DIETRICHS E; MAGNUSSON A; OPJORDSMOEN S
      ACUTE DYSTONIA CAUSED BY TETRABENAZINE - WHAT DOES IT TELL US ABOUT PATHOPHYSIOLOGY

      European journal of neurology
    61. VAHIDANSARI F; NAKABEPPU Y; ROBERTSON GS
      CONTRASTING EFFECTS OF CHRONIC CLOZAPINE, SEROQUEL(TM) (ICI-204,636) AND HALOPERIDOL ADMINISTRATION ON DELTA-FOSB-LIKE IMMUNOREACTIVITY IN THE RODENT FOREBRAIN

      European journal of neuroscience
    62. BONDOLFI G; BAUMANN P; DUFOUR H
      TREATMENT-RESISTANT SCHIZOPHRENIA - CLINICAL-EXPERIENCE WITH NEW ANTIPSYCHOTICS

      European neuropsychopharmacology
    63. COLLINS AA; REMINGTON G; COULTER K; BIRKETT K
      DEPRESSION IN SCHIZOPHRENIA - A COMPARISON OF 3 MEASURES

      Schizophrenia research
    64. ROBERTSON GS; FIBIGER HC
      EFFECTS OF OLANZAPINE ON REGIONAL C-FOS EXPRESSION IN RAT FOREBRAIN

      Neuropsychopharmacology
    65. DEUTCH AY; LEWIS DA; WHITEHEAD RE; ELSWORTH JD; IADAROLA MJ; REDMOND DE; ROTH RH
      EFFECTS OF D-2 DOPAMINE-RECEPTOR ANTAGONISTS ON FOS PROTEIN EXPRESSION IN THE STRIATAL COMPLEX AND ENTORHINAL CORTEX OF THE NONHUMAN PRIMATE

      Synapse
    66. MOLLER HJ
      NEW NEUROLEPTICS

      Nervenheilkunde
    67. STEINPREIS RE; KACZMAREK HJ; HARRINGTON A
      THE EFFECTS OF CYPROHEPTADINE ON VACUOUS JAW MOVEMENTS IN RATS - A COMPARISON WITH HALOPERIDOL AND CLOZAPINE

      Psychopharmacology bulletin
    68. STEINPREIS RE; KACZMAREK HJ; HARRINGTON A
      THE EFFECTS OF RACLOPRIDE ON VACUOUS JAW MOVEMENTS IN RATS FOLLOWING ACUTE ADMINISTRATION

      Physiology & behavior
    69. HIROI N; GRAYBIEL AM
      ATYPICAL AND TYPICAL NEUROLEPTIC TREATMENTS INDUCE DISTINCT PROGRAMS OF TRANSCRIPTION FACTOR EXPRESSION IN THE STRIATUM

      Journal of comparative neurology
    70. KOPALA LC
      SPONTANEOUS AND DRUG-INDUCED MOVEMENT-DISORDERS IN SCHIZOPHRENIA

      Acta psychiatrica Scandinavica
    71. CASEY DE
      BEHAVIORAL-EFFECTS OF SERTINDOLE, RISPERIDONE, CLOZAPINE AND HALOPERIDOL IN CEBUS MONKEYS

      Psychopharmacology
    72. PEACOCK L; SOLGAARD T; LUBLIN H; GERLACH J
      CLOZAPINE VERSUS TYPICAL ANTIPSYCHOTICS - A RETROSPECTIVE-STUDY AND PROSPECTIVE-STUDY OF EXTRAPYRAMIDAL SIDE-EFFECTS

      Psychopharmacology
    73. LIMINGA U; ANDREN PE; OHLUND LS; GUNNE LM
      HIGH-FREQUENCY ORAL MOVEMENTS INDUCED BY LONG-TERM ADMINISTRATION OF AMPEROZIDE BUT NOT FG5803 IN RATS

      Psychopharmacology
    74. BRUCKE T; WOBER C; PODREKA I; WOBERBINGOL C; ASENBAUM S; AULL S; WENGER S; ILIEVA D; HARASKOVANDERMEER C; WESSELY P; DEECKE L
      D-2 RECEPTOR BLOCKADE BY FLUNARIZINE AND CINNARIZINE EXPLAINS EXTRAPYRAMIDAL SIDE-EFFECTS - A SPECT STUDY

      Journal of cerebral blood flow and metabolism
    75. ONN SP; GRACE AA
      REPEATED TREATMENT WITH HALOPERIDOL AND CLOZAPINE EXERTS DIFFERENTIAL-EFFECTS ON DYE-COUPLING BETWEEN NEURONS IN SUBREGIONS OF STRIATUM ANDNUCLEUS-ACCUMBENS

      The Journal of neuroscience
    76. LEE HS; SONG DH; KIM JH; LEE YM; HAN ES; YOO KJ
      CYPROHEPTADINE AUGMENTATION OF HALOPERIDOL IN CHRONIC-SCHIZOPHRENIC PATIENTS - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

      International clinical psychopharmacology
    77. HOFFMAN DC; DONOVAN H
      CATALEPSY AS A RODENT MODEL FOR DETECTING ANTIPSYCHOTIC-DRUGS WITH EXTRAPYRAMIDAL SIDE-EFFECT LIABILITY

      Psychopharmacology
    78. FREEMAN HL
      DRUG DEVELOPMENT REPORT-(11) - CLINICAL ISSUES IN THE USE OF RISPERIDONE

      Journal of drug development
    79. LEE H; COONEY JM; LAWLOR BA
      THE USE OF RISPERIDONE, AN ATYPICAL NEUROLEPTIC, IN LEWY BODY DISEASE

      International journal of geriatric psychiatry
    80. ERIKSSON L
      REMOXIPRIDE IN THE TREATMENT OF PSYCHOSES

      Progress in neuro-psychopharmacology & biological psychiatry
    81. OHNO Y; ISHIDA K; IKEDA K; ISHIBASHI T; OKADA K; NAKAMURA M
      EVALUATION OF BRADYKINESIA INDUCTION BY SM-9018, A NOVEL 5-HT2 AND D-2 RECEPTOR ANTAGONIST, USING THE MOUSE POLE TEST

      Pharmacology, biochemistry and behavior
    82. BURKE MA; MCEVOY JP; RITCHIE JC
      A PILOT-STUDY OF A STRUCTURED INTERVIEW ADDRESSING SEXUAL FUNCTION INMEN WITH SCHIZOPHRENIA

      Biological psychiatry
    83. DIDRIKSEN M; CHRISTENSEN AV
      THE ATTENUATION OF SCHEDULE-INDUCED-POLYDIPSIA BY DOPAMINE BLOCKERS IS NOT AN EXPRESSION OF EXTRAPYRAMIDAL SIDE-EFFECT LIABILITY

      Behavioural pharmacology
    84. HARASKOVANDERMEER C; BRUCKE T; WENGER S; FISCHER P; DEECKE L; PODREKA I
      2 CASES OF LONG-TERM DOPAMINE D2 RECEPTOR BLOCKADE AFTER DEPOT NEUROLEPTICS

      Journal of neural transmission
    85. ABLORDEPPEY SY; BORNE RF
      DETECTION OF A NEUROTOXIC QUATERNARY PYRIDINIUM METABOLITE IN THE LIVER OF HALOPERIDOL-TREATED RATS

      Pharmacology, biochemistry and behavior
    86. MERCHANT KM; DORSA DM
      DIFFERENTIAL INDUCTION OF NEUROTENSIN AND C-FOS GENE-EXPRESSION BY TYPICAL VERSUS ATYPICAL ANTIPSYCHOTICS

      Proceedings of the National Academy of Sciences of the United Statesof America
    87. BOLDENWATSON C; WATSON MA; MURRAY KD; ISACKSON PJ; RICHELSON E
      HALOPERIDOL BUT NOT CLOZAPINE INCREASES NEUROTENSIN RECEPTOR MESSENGER-RNA LEVELS IN RAT SUBSTANTIA-NIGRA

      Journal of neurochemistry
    88. LAHTI RA; EVANS DL; STRATMAN NC; FIGUR LM
      DOPAMINE-D(4) VERSUS DOPAMINE D(2) RECEPTOR SELECTIVITY OF DOPAMINE RECEPTOR ANTAGONISTS - POSSIBLE THERAPEUTIC IMPLICATIONS

      European journal of pharmacology
    89. LUBLIN H; GERLACH J; PEACOCK L
      CHRONIC TREATMENT WITH THE D(1) RECEPTOR ANTAGONIST, SCH-23390, AND THE D(2) RECEPTOR ANTAGONIST, RACLOPRIDE, IN CEBUS MONKEYS WITHDRAWN FROM PREVIOUS HALOPERIDOL TREATMENT - EXTRAPYRAMIDAL SYNDROMES AND DOPAMINERGIC SUPERSENSITIVITY

      Psychopharmacology
    90. CASEY DE
      SEROTONERGIC AND DOPAMINERGIC ASPECTS OF NEUROLEPTIC-INDUCED EXTRAPYRAMIDAL SYNDROMES IN NONHUMAN-PRIMATES

      Psychopharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 11:44:33